» Articles » PMID: 31721075

PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma

Overview
Specialties Oncology
Pathology
Date 2019 Nov 14
PMID 31721075
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the performance characteristics of PD-L1 immunohistochemistry (IHC) combined positive scoring (CPS) in core biopsies and aspirate cell blocks from patients with head and neck squamous cell carcinoma (HNSqCCa). PD-L1 IHC using the SP263 antibody was performed on 20 paired cases which consisted of a small biopsy and an excisional specimen. The scores were compared at both the 1% and 20% cutpoints. Using the CPS result obtained from the resected specimen or excisional biopsy as the gold standard, PD-L1 IHC performed on the core biopsy or cell block identified 4 of 6 positive cases (66%) at the 20% cutpoint and 12 of 17 (70%) positive patients at the 1% cutpoint. False positive cases were uncommon at both cutpoints. CPS scoring should be used with caution in small biopsies from patients with HNSqCCa. A negative result should prompt consideration of an excisional biopsy and repeat testing.

Citing Articles

Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications.

Deuss E, Kurten C, Fehr L, Kahl L, Zimmer S, Kunzel J Cancers (Basel). 2024; 16(11).

PMID: 38893222 PMC: 11171694. DOI: 10.3390/cancers16112103.


PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study.

Lu H, Kuang D, Zhou P, Zeng J, Xia Q, Wang J J Clin Pathol. 2023; 78(2):88-95.

PMID: 37968103 PMC: 11874279. DOI: 10.1136/jcp-2023-209059.


Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations.

Bill R, Faquin W, Pai S Head Neck Pathol. 2023; 17(4):969-975.

PMID: 37930471 PMC: 10739626. DOI: 10.1007/s12105-023-01590-6.


Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma.

Kitichotkul K, Lertprasertsuke N, Kintarak S, Pongsiriwet S, Powcharoen W, Iamaroon A Heliyon. 2022; 8(10):e10667.

PMID: 36212017 PMC: 9535272. DOI: 10.1016/j.heliyon.2022.e10667.


From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.

Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X Front Immunol. 2022; 13:920021.

PMID: 35990664 PMC: 9382880. DOI: 10.3389/fimmu.2022.920021.


References
1.
Munari E, Zamboni G, Sighele G, Marconi M, Sommaggio M, Lunardi G . Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathol. 2018; 127(1):52-61. DOI: 10.1002/cncy.22083. View

2.
Poropatich K, Hernandez D, Fontanarosa J, Brown K, Woloschak G, Paintal A . Peritumoral cuffing by T-cell tumor-infiltrating lymphocytes distinguishes HPV-related oropharyngeal squamous cell carcinoma from oral cavity squamous cell carcinoma. J Oral Pathol Med. 2017; 46(10):972-978. DOI: 10.1111/jop.12605. View